For the year ending 2025-12-31, CADL had $17,227K increase in cash & cash equivalents over the period. -$38,898K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -38,182 |
| Depreciation expense | 845 |
| Impairment of fixed assets | 90 |
| Loss on the sale and disposal of fixed assets | -306 |
| Non-cash stock compensation expense | 3,817 |
| Non-cash lease expense | 321 |
| Non-cash interest expense | 138 |
| Change in fair value of warrant liabilities | -8,199 |
| Accretion of debt discount | 360 |
| Prepaid expenses and other current assets | 508 |
| Other assets | 24 |
| Accounts payable | 802 |
| Accrued expenses | 2,254 |
| Deferred income | 178 |
| Lease liability | -509 |
| Net cash used in operating activities | -38,311 |
| Purchase of fixed assets | 587 |
| Proceeds from the sale of fixed assets | 27 |
| Net cash used in investing activities | -560 |
| Proceeds from term loan, net of issuance costs | 47,946 |
| Proceeds from issuance of common stock in registered direct offering, net of issuance costs | 14,331 |
| Proceeds from sale of common stock through at-the-market offerings, net of issuance costs | 5,038 |
| Proceeds from option exercises | 516 |
| Principal payments on term loan payable to a bank | -11,733 |
| Net cash provided by financing activities | 56,098 |
| Net increase in cash, cash equivalents and restricted cash | 17,227 |
| Cash, cash equivalents and restricted cash at beginning of period | 102,920 |
| Cash, cash equivalents and restricted cash at end of period | 120,147 |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)